Navigation Links
Circulating Tumor Cells (CTCs) Prognostic Technologies Market Expected to Reach USD 2.16 Billion Globally in 2020

Albany, New York (PRWEB) July 22, 2014

According to a new market report published by Transparency Market Research “Circulating Circulating Tumor Cells (CTCs) Prognostic Technologies Market [Technologies: Tumor Cell Enrichment (Filtration, Centrifugation and Immunological & Immunomagnetic Methods) & Tumor Cell Detection (Molecular Methods and Optical Methods) and Applications: Prostate Cancer, Breast Cancer, Colorectal Cancer and Others] - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020,” the global circulating tumor cells (CTCs) prognostic technologies market was valued at USD 0.43 billion in 2013 and is expected to grow at a CAGR of 26.3% from 2014 to 2020, to reach an estimated value of USD 2.16 billion in 2020.

Title: Circulating Circulating Tumor Cells (CTCs) Prognostic Technologies Market
Published: June 2014
Pages: 100
Price:    US$ 4,795.00 (Single User)
For further inquiries, click here:

Circulating tumor cells (CTCs) are specialized rare cells, that have detached from the primary tumors of the body and disseminated in the vasculature system of the body, eventually causing metastasis. CTCs are composed of particular cells that act as seeds for successive development of additional metastatic tumors in essential distant organs, which is liable for the majority of cancer-related deaths. CTCs are not easily detected since these cells are present in less numbers in the blood stream. Therefore, detection of CTCs during the progression of the tumor provides a prognostic value of the tumor progression as well as evaluates the efficacy of therapeutic intervention.

According to the UICC (Union for International Cancer Control), over the next two decades, globally cancer cases will increase by nearly 75%, reaching almost to 25 million. Additionally, according to the ACS (American Cancer Society), it has been projected that in 2014, approximately 1,665,540 people would be diagnosed with cancer and around 585,720 people would die due to cancer, in the U.S. alone. This escalating base of cancer cases would need next generation prognostic technologies as well as targeted therapeutics for effective diagnosis and treatment of the disease, which would alternatively increase the demand for modern age CTCs prognostic technologies.

Browse full press release:

The circulating tumor cells (CTCs) prognostic technologies market has been primarily segmented in terms of technology and applications. The technology market further comprises tumor cell enrichment and tumor cell detection. Moreover, the tumor cell enrichment market is further segmented into filtration, centrifugation and immunomagnetic methods; among which, immunomagnetic methods accounted for the largest market due to widespread commercial availability and high effectiveness. Moreover, the CTCs detection market is further bifurcated into molecular methods and optical methods, among which, the optical methods segment is expected to foresee a remarkable growth rate of over 27.3% from 2014 to 2020. Furthermore, the application segment of this market consists of major application areas such as prostate cancer, breast cancer, colorectal cancer and others (lung cancer, ovarian cancer and pancreatic cancer).

Among the various applications of CTCs prognostic technologies, breast cancer and prostate cancer is expected to witness the fastest growth (27.1% & 25.2% respectively) during the forecast period owing to the high incidence and prevalence rate of these cancers and high adoption rate for CTCs technologies for therapeutic monitoring. However, it is also expected that colorectal cancer as well as other types of cancer will account for an admirable share of the market (24.2 % and 15% respectively in 2013) due to their rising prevalence rate and increasing research and development activities for discovering targeted therapeutics. It is expected that by the year 2020, the market value of CTCs prognostic technologies for application in prostate shall be worth more than USD 684.0 million.

Get report sample PDF copy from here:

In terms of geography, North America accounted for the largest CTCs prognostic technologies market in the year 2013 (over 50%) followed by Europe. However, Asia Pacific is estimated to exhibit the fastest growth rate owing to the expected rise in various types of cancer coupled with high research and development initiatives and growing adoption rate for advanced prognostic technologies. This market is highly consolidated in nature characterized by few players occupying approximately 70% of the overall market share. The major players of this market include Epic Sciences, Inc., Fluxion Biosciences, Inc., Silicon Biosystems, S.p.A., Rarecells USA, Inc. and Veridex, LLC.

Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA/Canada Toll Free: 866-552-3453
Email: sales(at)transparencymarketresearch(dot)com

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. A few circulating cancer cells could cue risk of metastases
2. New technology using florescent proteins tracks cancer cells circulating in the blood
3. NCCS and Clearbridge Biomedics open the regions first circulating tumor cell center
4. Circulating tumor cells in blood can predict a patients response to chemotherapy
5. New research finds flu shot effective regardless of circulating flu strain
6. Sous Vide Circulating Bath Systems Enable Chefs to Achieve Perfect Results
7. Detecting circulating tumor cells
8. New technology allows scientists to capture and preserve cancer cells circulating in the bloodstream
9. Capturing circulating cancer cells could provide insights into how disease spreads
10. Described novel regulator of a protein inactive in over 50 percent of human tumors
11. New combination drug controls tumor growth and metastasis in mice
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville ... is the only hospital in the region providing what is known as the ... pacing patients were revealed recently at a medical conference and published in The ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, “ ... a main “pain point” for merging or aligning healthcare provider organizations—when mergers and ... signed. This quick-read guidance suggests that failing to recognize the power of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... Dec. 1, 2015   Craneware, Inc ., ... solutions, today announced the company will showcase a ... ® solution at the American Society ... Meeting . The new features are focused on ... monitoring and managing enterprise-wide pharmacy charges to ensure ...
Breaking Medicine Technology: